Boston, MA 07/03/2013 (wallstreetpr) – Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) is a specialty pharmaceutical organization which is involved in the research, development, and commercialization of medical products and are in a combat to stop medication abuse. Acura Pharmaceuticals, Inc. is up by almost 24% in the premarket trading at $2.33. Acura Pharma has declared that Pfizer (PFE) will expand its commercialization of OXECTA tablets to healthcare providers by the end of this year. Acura is expected to receive a boost in the range of 5-25% on net sales of OXECTA. Acura has got an exclusive license for its technology in Aversion for Pfizer in countries like the U.S., Mexico and Canada for the usage of Oxecta, which helps in at once releasing oxycodone with a design that does not tamperand also which hinders the use of the drug recreationally. Acura Pharmaceuticals, Inc. is currently up (+144.34%) from its recent 52 week low which has prompted Equity Profile Report (EPR) to add this stock to their NASDAQ Gainers ‘Watch List’.
Analysts believe Acura Pharmaceuticals, Inc. is not at all over-valued at the ongoing price each share in the not so up 2’s and are poised to have a very bright future. FDA (Food and Drug Administration) recently announced that they were taking in mostly bad drugs of generic order one like generic OxyContin out of the market. This decision by FDA has come in as gift to Acura. FDA’s announcement was primarily to reduce the high amount of bad drugs. This combined with the extensive pipeline and technology that Acura has to stop this as it may lead to Acura benefitting big chunks of these markets that were initially dominated by low cost forms. These technologies with patents have about 21 million in the form of cash and assets, zero debt, and a huge pipeline, added with the FDA support; should be poised for quick and rapid growth. Analysts thus believe Acura will run with an upcoming catalyst of a news release of another contract with a big pharmacy, such as Wal-Mart or CVS, to start carrying Nexafed. With $27 million in cash and Nexafed starting to get on the market as a big competitor, Acura is enjoying it current market position.
